These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 7667977

  • 1. Cytomegalovirus infection in renal transplantation.
    Barton EN, Rigg KM, Morgan AG, Burden RP.
    West Indian Med J; 1995 Jun; 44(2):74-6. PubMed ID: 7667977
    [Abstract] [Full Text] [Related]

  • 2. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T, Lai WK, Mutimer D.
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [Abstract] [Full Text] [Related]

  • 3. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Late cytomegalovirus disease with atypical presentation in renal transplant patients: case reports.
    Boobes Y, Al Hakim M, Dastoor H, Bernieh B, Abdulkhalik S.
    Transplant Proc; 2004 Mar; 36(6):1841-3. PubMed ID: 15350493
    [Abstract] [Full Text] [Related]

  • 6. Initial cytomegalovirus prophylaxis with ganciclovir: no guarantee for prevention of late serious manifestations of CMV after solid organ transplantation.
    Zandberg M, de Maar EF, Hofker HS, Homan van der Heide JJ, Rosati S, van Son WJ.
    Neth J Med; 2005 Nov; 63(10):408-12. PubMed ID: 16301763
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients.
    Rondeau E, Bourgeon B, Peraldi MN, Lang P, Buisson C, Schulte KM, Weill B, Sraer JD.
    Nephrol Dial Transplant; 1993 Nov; 8(9):858-62. PubMed ID: 8255520
    [Abstract] [Full Text] [Related]

  • 9. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
    Winston DJ, Busuttil RW.
    Transplantation; 2004 Jan 27; 77(2):305-8. PubMed ID: 14742998
    [Abstract] [Full Text] [Related]

  • 10. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G.
    Clin Transplant; 1996 Dec 27; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [Abstract] [Full Text] [Related]

  • 11. [Evaluation of viral load and antigenemia as markers for relapse cytomegalovirus infection in renal transplant recipients].
    Franco A, Serrano R, Gimeno A, de Juan J, Merino E, Jiménez del Cerro L, Olivares J.
    Nefrologia; 2007 Dec 27; 27(2):202-8. PubMed ID: 17564566
    [Abstract] [Full Text] [Related]

  • 12. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S, Ynares C, Dummer S, Helderman JH.
    Kidney Int Suppl; 1996 Dec 27; 57():S62-5. PubMed ID: 8941924
    [Abstract] [Full Text] [Related]

  • 13. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep 27; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

  • 14. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Sep 27; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Sep 27; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T, Jindra P, Svecová M, Kormunda S, Opatrný K, Treska V.
    J Clin Virol; 2006 Jun 27; 36(2):146-51. PubMed ID: 16531113
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus infection in renal transplant recipients.
    Carstens J, Andersen HK, Spencer E, Madsen M.
    Transpl Infect Dis; 2006 Dec 27; 8(4):203-12. PubMed ID: 17116133
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus infection in seronegative patients treated with prophylaxis: case-controlled study.
    Moreno de la Higuera Díaz MA, Calvo Romero N, Sánchez-Fructuoso A, Conesa J, Marques Vidas M, Prats D, Barrientos Guzmán A.
    Transplant Proc; 2007 Sep 27; 39(7):2231-2. PubMed ID: 17889147
    [Abstract] [Full Text] [Related]

  • 20. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V, Bravo S, Van Renterghem L, de Moerloose B, Benoit Y, Laureys G, Dhooge C.
    Transpl Infect Dis; 2008 Feb 27; 10(1):19-23. PubMed ID: 17511814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.